Latest On Alkermes plc (ALKS):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-08 20:45 EST | News | Alkermes board declines to endorse any Sarissa nominees | N/A |  |
| 2023-04-27 02:45 EST | News | Alkermes plc (ALKS) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-04-26 14:47 EST | News | Alkermes Non-GAAP EPS of $0.01 beats by $0.02, revenue of $287.6M beats by $6.41M | N/A | |
| 2023-04-25 14:32 EST | News | Alkermes gets tribunal award in J&J license deal arbitration | N/A | |
| 2023-04-18 20:15 EST | News | Alkermes files SEC document for planned separation of oncology business | N/A | |
About Alkermes plc (ALKS):
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of mul read more...tiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI (olanzapine/samidorphan), an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; a license agreement with Acorda Therapeutics, Inc.; and a license and collaboration agreement with Biogen Swiss Manufacturing GmbH. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
General
- Name Alkermes plc
- Symbol ALKS
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 2,245
- Last Split Factor2:1
- Last Split Date2000-05-15
- Fiscal Year EndDecember
- IPO Date1991-07-16
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.alkermes.com
Valuation
- Forward PE 40.49
- Price/Sales (Trailing 12 Mt.) 2.97
- Price/Book (Most Recent Quarter) 2.9
- Enterprise Value Revenue 2.76
- Enterprise Value EBITDA 97.47
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $0.45
- Next Year EPS Estimate $0.94
- Next Quarter EPS Estimate $0.07
- Profit Margin -11%
- Operating Margin -11%
- Return on Assets -4%
- Return on Equity -10%
- Revenue 1.04 billion
- Earnings Per Share -$1.17
- Revenue Per Share $6.54
- Gross Profit 860.44 million
- Quarterly Earnings Growth -32.2%
Highlights
- Market Capitalization 3.12 billion
- EBITDA 3.81 million
- PE Ratio 16.23
- PEG Ratio -1057.29
- Analyst Target Price $21.89
- Book Value Per Share $6.70
Share Statistics
- Shares Outstanding 159.24 million
- Shares Float 157.43 million
- % Held by Insiders 93%
- % Held by Institutions 100.79%
- Shares Short 11.34 million
- Shares Short Prior Month 11.28 million
- Short Ratio 8.37
- Short % of Float 10%
- Short % of Shares Outstanding 7%
Technicals
- Beta 0.93
- 52 Week High $23.92
- 52 Week Low $12.71
- 50 Day Moving Average 20.28
- 200 Day Moving Average 18.96
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
ESG Rating
Alkermes plc (ALKS) Dividend Calendar:
Alkermes plc (ALKS) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Alkermes plc (ALKS) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Alkermes plc (ALKS) Chart:
Alkermes plc (ALKS) News:
Below you will find a list of latest news for Alkermes plc (ALKS) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Alkermes plc (ALKS) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest ALKS Trades:
Alkermes plc (ALKS) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-10-29 | 8-K (Current report) | |
| 2020-10-29 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-10-09 | 8-K (Current report) | |
| 2020-10-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-10 | SC 13G/A (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-09-09 | 8-K (Current report) | |
| 2020-07-29 | 8-K (Current report) | |
| 2020-07-29 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-07-29 | S-8 POS (Securities to be offered to employees in employee benefit plans, post-effective amendments) | |
| 2020-07-29 | S-8 POS (Securities to be offered to employees in employee benefit plans, post-effective amendments) | |
| 2020-07-29 | S-8 POS (Securities to be offered to employees in employee benefit plans, post-effective amendments) | |
| 2020-07-29 | S-8 POS (Securities to be offered to employees in employee benefit plans, post-effective amendments) | |
| 2020-07-29 | S-8 POS (Securities to be offered to employees in employee benefit plans, post-effective amendments) | |
| 2020-07-29 | S-8 (Securities to be offered to employees in employee benefit plans) | |
| 2020-07-15 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-08 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-08 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-08 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-08 | 4 (Statement of changes in beneficial ownership of securities) | |
Alkermes plc (ALKS) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Alkermes plc (ALKS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 93%
Institutional Ownership: 10079%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-10-01 | PAUL J MITCHELL | Director | Buy | 20,000.00 | 14.92 | 298,400.00 | 27,000.00 | |
| 2020-10-01 | PAUL J MITCHELL | Director | Sell | 20,000.00 | 16.61 | 332,262.00 | 7,000.00 | |
| 2020-09-28 | DAVID W ANSTICE | Director | Sell | 17,832.00 | 16.79 | 299,310.12 | 68,381.00 | |
| 2020-09-28 | DAVID W ANSTICE | Director | Buy | 20,000.00 | 14.92 | 298,400.00 | 86,213.00 | |
| 2020-07-14 | MICHAEL J LANDINE | SVP, Corp Dev., Alkermes, Inc. | Buy | 5,523.00 | 18.11 | 99,993.92 | 207,345.00 | |
| 2020-06-07 | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Buy | 1,250.00 | 15,201.00 | | ||
| 2020-06-05 | Christian Todd Nichols | SVP, Chief Commercial Officer | Buy | 3,500.00 | 3,500.00 | | ||
| 2020-05-14 | RICHARD F POPS | Director and CEO, Alkermes plc | Sell | 75,000.00 | 15.00 | 1,125,232.50 | 759,094.00 | |
| 2020-05-14 | RICHARD F POPS | Director and CEO, Alkermes plc | Buy | 75,000.00 | 11.74 | 880,500.00 | 834,094.00 | |
| 2020-05-14 | JAMES M FRATES | SVP, Alks Inc; CFO ALKS | Buy | 21,983.00 | 11.74 | 258,080.42 | 91,828.00 | |
| 2020-05-13 | Iain Michael Brown | SVP Finance & CAO, Alks Inc. | Sell | 6,250.00 | 15.39 | 96,193.13 | 38,581.00 | |
| 2020-05-13 | Iain Michael Brown | SVP Finance & CAO, Alks Inc. | Buy | 6,250.00 | 11.74 | 73,375.00 | 44,831.00 | |
| 2020-05-12 | MICHAEL J LANDINE | SVP, Corp Dev., Alkermes, Inc. | Sell | 18,000.00 | 15.75 | 283,469.40 | 201,822.00 | |
| 2020-05-12 | MICHAEL J LANDINE | SVP, Corp Dev., Alkermes, Inc. | Buy | 18,000.00 | 11.74 | 211,320.00 | 219,822.00 | |
| 2020-05-07 | RICHARD F POPS | Director and CEO, Alkermes plc | Sell | 50,000.00 | 14.63 | 731,265.00 | 759,094.00 | |
| 2020-05-07 | RICHARD F POPS | Director and CEO, Alkermes plc | Buy | 50,000.00 | 11.74 | 587,000.00 | 809,094.00 | |
| 2020-05-05 | MICHAEL J LANDINE | SVP, Corp Dev., Alkermes, Inc. | Sell | 25,000.00 | 14.06 | 351,425.00 | 201,822.00 | |
| 2020-05-05 | MICHAEL J LANDINE | SVP, Corp Dev., Alkermes, Inc. | Buy | 25,000.00 | 11.74 | 293,500.00 | 226,822.00 | |
| 2020-04-02 | RICHARD F POPS | Director and CEO, Alkermes plc | Sell | 50,000.00 | 13.79 | 689,500.00 | 759,094.00 | |
| 2020-04-02 | RICHARD F POPS | Director and CEO, Alkermes plc | Buy | 50,000.00 | 11.74 | 587,000.00 | 809,094.00 | |